Filtros de búsqueda

Lista de obras de

A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients

artículo científico publicado en 2019

A Validated Method for Quantification of Dolutegravir Using Ultra Performance Liquid Chromatography Coupled With UV Detection

artículo científico publicado en 2016

A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects

artículo científico publicado en 2008

A randomised, placebo-controlled, first-in-human study of a novel clade C therapeutic peptide vaccine administered ex vivo to autologous white blood cells in HIV infected individuals

artículo científico publicado en 2013

A review of the clinical pharmacology of maraviroc. Introduction

artículo científico publicado en 2008

Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients

scientific article published on 01 January 2007

Alpha 1-acid glycoprotein levels in human immunodeficiency virus-infected subjects on antiretroviral regimens

artículo científico publicado en 2002

An open-label, randomized study of the impact on insulin sensitivity, lipid profile and vascular inflammation by treatment with lopinavir/ritonavir or raltegravir in HIV-negative male volunteers

artículo científico publicado en 2016

Antiretroviral dose optimization: the future of efavirenz 400 mg dosing

artículo científico

Antiretroviral resistance and management after pre-exposure to prophylaxis

artículo científico publicado en 2020

Antiretroviral therapy to reduce the sexual transmission of HIV.

artículo científico publicado en 2003

Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity

artículo científico publicado en 2014

Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a

artículo científico publicado en 2017

Associations between widespread pain and sleep quality in people with HIV

artículo científico publicado en 2020

Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen

artículo científico publicado en 2004

Authors' reply: pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives

artículo científico publicado en 2015

Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily

artículo científico publicado en 2005

Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis

artículo científico publicado en 2016

British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011

article

British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

article

British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.).

artículo científico publicado en 2014

British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012.

artículo científico publicado en 2012

British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015

article

COVID-19 in patients with HIV

artículo científico publicado en 2020

Can we boost enough without ritonavir?

artículo científico publicado en 2004

Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults

artículo científico publicado en 2011

Changes in functional connectivity in people with HIV switching antiretroviral therapy

scientific article published on 04 June 2020

Characterization of low level viraemia in HIV-infected patients receiving boosted protease inhibitor-based antiretroviral regimens

artículo científico publicado en 2019

Clearance of 14-3-3 protein from cerebrospinal fluid heralds the resolution of bacterial meningitis.

artículo científico publicado en 2003

Clinical management of ageing people living with HIV in Europe: the view of the care providers

scientific article published on 20 March 2020

Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics

artículo científico publicado en 2002

Coadministration of Atazanavir-Ritonavir and Zinc Sulfate: Impact on Hyperbilirubinemia and Pharmacokinetics ⬇️

artículo científico publicado el 20 de mayo de 2013

Cohort profile: The Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study

artículo científico publicado en 2018

Comorbidity Indices in People with HIV and Considerations for COVID-19 Outcomes

artículo científico publicado en 2020

Comparison of efavirenz and protease inhibitor based combination antiretroviral therapy regimens in treatment-naïve people living with HIV with baseline resistance

artículo científico publicado en 2016

Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings

artículo científico publicado en 2017

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

artículo científico publicado en 2015

Correction to: Clinical management of ageing people living with HIV in Europe: the view of the care providers

artículo científico publicado en 2020

Critical Review: What Dose of Rifabutin Is Recommended With Antiretroviral Therapy?

artículo científico publicado en 2016

Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy

artículo científico publicado en 2005

Cytotoxic chemotherapy and the evolution of cellular and viral resistance to antiretroviral therapy in HIV- infected individuals with lymphoma

artículo científico publicado en 2016

Defining cognitive impairment in people-living-with-HIV: the POPPY study.

artículo científico publicado en 2016

Depression, lifestyle factors and cognitive function in people living with HIV and comparable HIV-negative controls

scientific article published on 08 February 2019

Detection of stavudine concentrations in plasma of HIV-infected patients taking zidovudine

artículo científico publicado en 2004

Development of long-acting ARV’s

article

Development, Validation, and Field-Testing of an Instrument for Clinical Assessment of HIV-Associated Neuropathy and Neuropathic Pain in Resource-Restricted and Large Population Study Settings

artículo científico publicado en 2016

Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response

scientific article published on 01 April 2006

Does pregnancy affect the pharmacokinetics of efavirenz?

artículo científico publicado en 2014

Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake

artículo científico publicado en 2015

Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis

artículo científico publicado en 2020

Dosing antiretroviral medication when crossing time zones: a review.

artículo científico

Drug interactions and the role of pharmacokinetic trials in guiding choices in first-line HIV therapy in low-income and middle-income countries.

artículo científico publicado en 2017

Drug-drug interactions involving new antiretroviral drugs and drug classes

artículo científico publicado en 2009

Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial

artículo científico publicado en 2005

Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults.

artículo científico publicado en 2012

Effect of a modified saquinavir/ritonavir dosing regimen with lower dose lead-in phase on QTc interval, pharmacokinetics, antiviral activity and safety in treatment-naïve HIV-1-infected patients

artículo científico publicado en 2015

Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men ⬇️

artículo científico publicado el 1 de enero de 2010

Effect of hyperbilirubinaemia on neurocognitive, renal, bone and cardiovascular markers in HIV infection treated with boosted protease inhibitors

artículo científico publicado en 2014

Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers

artículo científico publicado en 2006

Effects of different meal compositions and fasted state on the oral bioavailability of etravirine

artículo científico publicado en 2008

Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients

artículo científico publicado en 2011

Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults

artículo científico publicado en 2012

Evaluation of the psychometric properties of the HIV Disability Questionnaire among adults living with HIV in the United Kingdom: A cross-sectional self-report measurement study

scientific article published on 10 July 2019

Ex-vivo recognition of late-lytic CD8 epitopes specific for Kaposi's sarcoma-associated herpesvirus (KSHV) by HIV/KSHV-coinfected individuals.

artículo científico publicado en 2011

Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics

artículo científico publicado en 2020

Guidelines in the context of medical ethics

artículo científico publicado en 2019

Host determinants of antiretroviral drug activity

artículo científico publicado en 2005

How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials

artículo científico publicado en 2009

How recent findings on the pharmacokinetics and pharmacodynamics of integrase inhibitors can inform clinical use.

artículo científico publicado en 2016

Iatrogenic Cushing's syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies.

artículo científico publicado en 2016

Impact of NRTI backbone on renal, bone and cardiovascular markers in HIV-infected individuals receiving a boosted protease inhibitor

artículo científico publicado en 2014

Improved Central Nervous System Symptoms in People with HIV without Objective Neuropsychiatric Complaints Switching from Efavirenz to Rilpivirine Containing cART

artículo científico publicado en 2019

Incidental findings in elderly people living with HIV undergoing computed tomography coronary artery calcium scoring

artículo científico publicado en 2020

Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?

artículo científico publicado en 2019

Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition

artículo científico publicado en 2019

Increasing use of 'party drugs' in people living with HIV on antiretrovirals: a concern for patient safety.

artículo científico publicado en 2015

Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients

artículo científico publicado en 2006

InterPrEP. Internet-based pre-exposure prophylaxis with generic tenofovir DF/emtricitabine in London: an analysis of outcomes in 641 patients

artículo científico publicado en 2017

InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes

artículo científico publicado en 2017

Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients

artículo científico publicado en 2005

Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring ⬇️

artículo científico publicado el 2 de mayo de 2003

Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients

artículo científico publicado en 2004

Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarrays

artículo científico publicado en 2010

Ketoconazole and lopinavir/ritonavir coadministration: boosting beyond boosting.

artículo científico publicado en 2003

Kidney transplantation in HIV-positive adults: the UK experience

artículo científico publicado en 2013

Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate

artículo científico publicado en 2005

Lactacidemia in asymptomatic HIV-infected subjects receiving nucleoside reverse-transcriptase inhibitors

artículo científico publicado en 2002

Level of agreement between frequently used cardiovascular risk calculators in people living with HIV

scientific article published on 14 March 2019

Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals

artículo científico publicado en 2007

Long-acting antiviral agents for HIV treatment

artículo científico

Long-acting cabotegravir for prevention: hope versus reality

artículo científico publicado en 2017

Lopinavir measurement in pleural effusion in a human immunodeficiency virus type 1-infected patient with kaposi's sarcoma

artículo científico publicado en 2002

Lopinavir protein binding in vivo through the 12-hour dosing interval

artículo científico publicado en 2004

Lopinavir/ritonavir absorption in a gastrectomized patient

artículo científico publicado en 2003

Measurement of Retinal Vessels as a Biomarker of Cerebrovascular Aging in Older HIV-Positive Men Compared With Controls

artículo científico publicado en 2017

Multimodality assessment of sleep outcomes in people living with HIV performed using validated sleep questionnaires

scientific article published on 01 September 2020

Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin

artículo científico publicado en 2010

New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents

artículo científico

No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals

artículo científico publicado en 2014

Non-immunogenicity of overlapping gag peptides pulsed on autologous cells after vaccination of HIV infected individuals ⬇️

artículo científico publicado en 2013

Nucleoside/nucleotide reverse transcriptase inhibitor drug interactions

artículo científico publicado en 2004

Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge

artículo científico publicado en 2017

Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge

artículo científico publicado en 2017

Outcomes of kidney transplantation in HIV-positive patients: the UK experience

artículo científico publicado en 2013

Pain in people living with HIV and its association with healthcare resource use, well-being and functional status

article

Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection

artículo científico publicado en 2019

Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing

artículo científico publicado en 2008

Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives

artículo científico publicado en 2015

Pharmacokinetic considerations for combining 2 protease inhibitors

artículo científico publicado en 2004

Pharmacokinetic evaluation of indinavir and indinavir/ritonavir-containing antiretroviral regimens in a clinical setting

artículo científico publicado en 2002

Pharmacokinetic implications of resistance

Pharmacokinetics (PK) of ethinylestradiol/levonorgestrel co-administered with atazanavir/cobicistat

artículo científico publicado en 2019

Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance

artículo científico publicado en 2007

Pharmacokinetics and pharmacodynamics in HAART and antibiotic therapy

artículo científico publicado en 2007

Pharmacokinetics and pharmacodynamics of drug interactions involving HIV-1 protease inhibitors.

artículo científico publicado en 2004

Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs

scientific article published on 18 August 2008

Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals

artículo científico publicado en 2017

Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers.

artículo científico publicado en 2009

Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers.

artículo científico publicado en 2011

Pharmacokinetics of Abacavir and its Anabolite Carbovir Triphosphate without and with Darunavir/ Ritonavir or Raltegravir in HIV-Infected Subjects ⬇️

artículo científico publicado el 1 de enero de 2012

Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals

artículo científico publicado en 2019

Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation ⬇️

artículo científico publicado el 27 de junio de 2011

Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation

artículo científico publicado en 2008

Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin

scientific article published on 16 April 2019

Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers

artículo científico publicado en 2019

Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers

scientific article published on 01 May 2019

Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study

artículo científico publicado en 2011

Pharmacokinetics of once-daily doravirine over 72 h following drug cessation

artículo científico publicado en 2020

Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.

artículo científico publicado en 2004

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers

artículo científico publicado en 2010

Pharmacokinetics of saquinavir co-administered with cimetidine

artículo científico publicado en 2002

Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects

artículo científico publicado en 2005

Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses

scientific article published on 01 August 2006

Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers

artículo científico publicado en 2014

Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum

artículo científico publicado en 2018

Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients

artículo científico publicado en 2008

Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus-associated cardiovascular risk

artículo científico publicado en 2019

Pharmacology lessons from chemoprophylaxis studies

artículo científico publicado en 2014

Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents

artículo científico publicado en 2009

Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects

artículo científico publicado en 2010

Plasma NRTI concentration and their associations with liver and renal parameters in people living with HIV

artículo científico publicado en 2020

Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.

artículo científico publicado en 2015

Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals ⬇️

artículo científico publicado el 15 de diciembre de 2011

Polypharmacy and drug-drug interactions in older and younger people living with HIV: the POPPY study

scientific article published on 01 January 2019

Polypharmacy and evaluation of anticholinergic risk in a cohort of elderly people living with HIV

artículo científico publicado en 2019

Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals

artículo científico publicado en 2012

Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the N

artículo científico publicado en 2020

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers

artículo científico publicado en 2009

Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals

artículo científico publicado en 2008

Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies

artículo científico publicado en 2006

Prevention of atherosclerosis in patients living with HIV.

artículo científico publicado en 2009

Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1.

artículo científico publicado en 2009

Protein binding in antiretroviral therapies

artículo científico publicado en 2003

Quantification of rilpivirine in human plasma, cervicovaginal fluid, rectal fluid and genital/rectal mucosal tissues using liquid chromatography-tandem mass spectrometry

artículo científico publicado en 2014

Quantification of tenofovir disoproxil fumarate and emtricitabine in generic pre-exposure prophylaxis tablets obtained from the internet

scientific article published on 09 May 2019

Raltegravir switch improves hepatitis C transaminitis in HIV-1 and hepatitis C (HCV) co-infected individuals.

artículo científico publicado en 2012

Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps

article

Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide

scientific article published on 01 June 2019

Rilpivirine long-acting for the prevention and treatment of HIV infection

artículo científico publicado en 2018

Risk factors and impact of patterns of co-occurring comorbidities in people living with HIV

artículo científico publicado en 2019

Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.

artículo científico publicado en 2013

Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial

artículo científico

Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA).

artículo científico publicado en 2015

Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies

artículo científico publicado en 2011

Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?

artículo científico publicado en 2014

Should we switch to a 50-mg boosting dose of ritonavir for selected protease inhibitors?

artículo científico publicado en 2011

Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach.

artículo científico publicado en 2014

Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach.

artículo científico publicado en 2015

Simultaneous determination of rifampicin and efavirenz in plasma

artículo científico publicado en 2002

Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies

artículo científico publicado en 2013

Simvastatin co-prescribed with protease inhibitors despite dangerous drug interactions

artículo científico publicado en 2007

Steady-State Pharmacokinetics of Lopinavir Plus Ritonavir When Administered Under Different Meal Conditions in HIV-Infected Ugandan Adults ⬇️

artículo científico publicado el 1 de julio de 2012

Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients

artículo científico publicado en 2004

Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults

artículo científico publicado en 2008

Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects ⬇️

artículo científico publicado en 2009

Stopping antiretroviral therapy

artículo científico publicado en 2007

Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.

artículo científico publicado en 2010

Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy

artículo científico publicado en 2014

Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention

artículo científico publicado en 2013

The clinical implications of antiretroviral pharmacogenomics

artículo científico publicado en 2006

The clinical pharmacology of antiretrovirals in development

artículo científico publicado en 2006

The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma.

artículo científico publicado en 2016

The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma.

artículo científico publicado en 2009

The management of HIV-1 protease inhibitor pharmacokinetic interactions

artículo científico publicado en 2005

The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.

artículo científico publicado en 2015

The pharmacokinetics of HIV protease inhibitor combinations

artículo científico publicado en 2005

The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy

artículo científico publicado en 2015

The predictors of pain extent in people living with HIV

artículo científico publicado en 2020

The relationship between nevirapine plasma concentrations and abnormal liver function tests

artículo científico publicado en 2004

The triumph of HIV treatment: another new antiretroviral

artículo científico publicado en 2017

The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects

artículo científico publicado en 2002

Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs.

artículo científico publicado en 2005

Transmitted antiretroviral drug resistance in treatment naïve HIV-infected persons in London in 2011 to 2013

artículo científico publicado en 2014

Transmitted antiretroviral resistance in a large HIV directorate 2011-2014: a response.

artículo científico publicado en 2015

Treating advanced HIV infection

artículo científico publicado en 2003

Twenty years of boosting antiretroviral agents: where are we today?

artículo científico publicado en 2015

Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment

artículo científico publicado en 2002

Unexpected drug interactions and adverse events with antiretroviral drugs

artículo científico publicado en 2004

Unexpected rapid weight gain in a patient with HIV and anorexia

artículo científico publicado en 2015

Use of Coronary Artery Calcium Scoring to improve cardiovascular risk stratification and guide decisions to start statin therapy in People living with HIV

scientific article published on 07 May 2020

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda